81,932 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Wealthfront Advisers LLC

Wealthfront Advisers LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 81,932 shares of the biotechnology company's stock, valued at approximately $2,728,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Seizert Capital Partners LLC boosted its holdings in shares of Exelixis by 8.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock valued at $12,195,000 after acquiring an additional 34,875 shares during the last quarter. Tri Ri Asset Management Corp purchased a new stake in Exelixis in the third quarter valued at $4,396,000. Blue Trust Inc. grew its position in Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after purchasing an additional 8,208 shares during the period. Navellier & Associates Inc. purchased a new position in shares of Exelixis during the 3rd quarter valued at about $573,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Exelixis by 48.2% in the 3rd quarter. Intech Investment Management LLC now owns 232,041 shares of the biotechnology company's stock valued at $6,021,000 after buying an additional 75,489 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Activity at Exelixis

In other news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the sale, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EXEL. Truist Financial raised their target price on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, January 27th. StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Brookline Capital Management assumed coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a "buy" rating on the stock. Barclays lifted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Finally, JMP Securities reissued a "market outperform" rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Remove Ads

Exelixis Price Performance

EXEL opened at $36.80 on Friday. The company's 50 day simple moving average is $35.25 and its two-hundred day simple moving average is $32.33. The firm has a market capitalization of $10.30 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.